Clearside Biomedical Inc (NASDAQ:CLSD) is a company that focuses in the development of working pharmacological therapies. The therapies by this business guru help in dealing with the blinding diseases of the eye and other vision defects. This business has its headquarters in Alpharetta, Georgia. The results of the Phase 3 clinical trial are already out. However, the study failed to meet its primary end point.
Current state of affairs
Clearside Biomedical seeks to find solutions that help handle retinal vein occlusion (‘RVO”).Its latest study sought to establish the effectiveness of XIPERE in combination with intravitreal Eylea monotherapy.
The study took into account a group of patients under the combination treatment arm. Reports indicate that the study used these as the trial’s primary endpoint. This study struck a comparison between this and the proportion under the intravitreal Eylea-alone control arm. This study also targeted establishing what worked in line with correcting visual acuity.
A closer outlook
The SAPPHIRE trial involved two arms and the company has a lot to learn from the results. They indicate that almost 50% of patients in each of the arms showcased remarkable improvements. Each patient witnessed a 15 letter enhancement in vision.
The patients treated with XIPERE in close combination with intravitreal Eylea didn’t receive the expected additional benefits. That has become a major cause for concern in line with the recent study.
The President of Clearside Daniel White opined, “In light of these 8-week topline data, we plan to discontinue clinical development of combination therapy for RVO, which includes SAPPHIRE and its companion Phase 3 clinical trial, TOPAZ.”
Mr. White says that uveitis serves them with a remarkable opportunity. This of course happens to be the company’s primary indication. The official also speaks in relation to the increased acceptance and awareness in line with XIPERE.
The strong clinical profile of the substance moves the company a notch higher in the list of innovative companies.
It seeks to work on the product to ensure its effectiveness in handling uveitic macular edema. The company outlines that before the end of this particular year it will have submitted its NDA.
